Skip to main content
Fig. 5 | Acta Neuropathologica Communications

Fig. 5

From: Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma

Fig. 5

Prognostic relevance of P-RPS6 and P-PRAS40 in treatment groups of MGMT-promoter unmethylated tumors. a-b Kaplan-Meier survival curves for patients with MGMT promoter unmethylated GBs treated with nimotuzumab or placebo (control) for dichotomized histological subgroups (median split, above median: high, below and equal to median low) for P-RPS6 (a) and P-PRAS40 (b). P values were calculated using the Wilcoxon test

Back to article page